Abraxis BioScience, Inc. Appoints Rick Rodgers Chief Financial Officer
July 10, 2009
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII - News), an integrated, global biopharmaceutical company, today announced the appointment of Rick Rodgers as Senior Vice President and Chief Financial Officer, succeeding David O'Toole.
"Rick is a dynamic executive who is well adept at leading organizations that are experiencing rapid growth," said Lonnie Moulder, President and Chief Executive Officer. "Having worked together in the recent past, I can attest to his broad range of abilities and financial acumen and am confident he will be a valuable asset to the Abraxis team. I would also like to acknowledge David's many contributions to the company and appreciate his guidance in effecting a smooth transition."
Mr. Rodgers most recently was Senior Vice President, Controller and Chief Accounting Officer of MGI Pharma until the company's acquisition by Eisai Corporation in 2008. In 2003, Mr. Rodgers was Corporate Controller of MedSource Technologies and from 1997 to 2002, he held various senior positions at ADC Telecommunications Inc. Prior to that, he held finance and accounting positions at several private and public companies. Mr. Rodgers began his financial career in accounting at Arthur Anderson & Co. Mr. Rodgers earned his bachelor of science degree in Financial Accounting from St. Cloud State University, Minn., and his master of business administration degree in Finance from the University of Minnesota, Carlson School of Business.
About Abraxis BioScience, Inc.
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 36 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.